Prioritizing Risk Analysis Quality Control Plans Based on Sigma-metrics

Clinics in Laboratory Medicine

Volumn 33, Issue 1, 2013, Pages 41-53

  Westgard, Sten ^a  

^a Westgard QC   (United States)

Author keywords

Failure mode and effects analysis; Quality control design; Quality Control Plan; Risk analysis; Risk management; Sigma metrics; Six Sigma

Indexed keywords

ACCURACY; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL LABORATORY; HEALTH CARE PLANNING; MEASUREMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SIX SIGMA METRIC; STANDARDIZATION; SYSTEMATIC ERROR; TOTAL QUALITY MANAGEMENT;

EID: 84872482109     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2012.11.008     Document Type: Review

References (25)

1. Nichols J.H. Laboratory quality control based on risk management. Ann Saudi Med 2011, 31(3):223-228.
2. CLIA Individualized Quality Control Plan (IQCP) benefits. Available at: . Accessed September 26, 2012. http://www1b.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/IQCPbenefits.pdf.
3. Barry R. The Six Sigma Book for Healthcare 2002, Health Administration Press, Chicago.
4. Pande P.S., Neuman R.P., Cabanagh R.R. The Six Sigma way: how GE, Motorola, and other top companies are honing their performance 2000, McGraw-Hill, New York.
5. Harry M., Schroder R. Six Sigma: the breakthrough management strategy revolutionizing the world's top corporations 2000, Doubleday, New York.
6. Frankel H.L., Crede W.B., Topal J.E., et al. Use of corporate Six Sigma performance-improvement strategies to reduce incidence of catheter-related bloodstream infection in a surgical ICU. J Am Coll Surg 2005, 201:349-358.
7. Egan S., Murphy P.G., Fennell J.P., et al. Using Six Sigma to improve once daily gentamicin dosing and therapeutic drug monitoring performance. BMJ Qual Saf 2012, 21:1042-1051.
8. Nevalainen D., Berte L., Kraft C., et al. Evaluating laboratory performance on quality indicators with the Six Sigma scale. Arch Pathol Lab Med 2000, 124:516-519.
9. Antonia L., Gloria T., Isabel L., et al. Quality Indicators and specifications for key analytical-extraanalytical processes in the laboratory. Five years' experience using the Six Sigma concept. Clin Chem Lab Med 2011, 49(3):463-470.
10. Sciacovelli L., Sonntag O., Padoan A., et al. Monitoring quality indicators in laboratory medicine does not automatically result in quality improvement. Clin Chem Lab Med 2012, 50(3):463-469.
11. Centers for Medicaid and Medicare CLIA proficiency testing criteria. Fed Regist 1992, 57(40):7002-7186.
12. RiliBÄK (Richtlinien der Bundesärztekammer). The term 'RiliBÄK' is an abbreviation meaning literally the Guidelines (" Rili" ) of the German Federal Medical Council (BÄK). [in German]. Available at: . Accessed October 8, 2012. http://www.westgard.com/rilibak.htm.
13. Allowable limits of performance. Available at: . Accessed October 8, 2012. http://www.rcpaqap.com.au/chempath/documents/uploadedfiles/344_GSC%2520Revision%2520of%2520allowable%2520limits%2520August%25202010.pdf.
14. Ricos C., Alvarez V., Cava F., et al. Current databases on biologic variation: pros, cons and progress. Scand J Clin Lab Invest 1999, 59:491-500.
15. Westgard J.O., Carey R.N., Wold S. Criteria for judging precision and accuracy in method development and evaluation. Clin Chem 1974, 20:825-833.
16. Ehrmeyer S.J., Laessig R.L., Leinweber J.E., et al. 1990 Medicare/CLIA final rules for proficiency testing: minimum intralaboratory performance characteristics (CV and bias) needed to pass. Clin Chem 1990, 36:1736-1740.
17. Westgard J.O., Burnett R. Precision requirements for cost-effective operation of analytical processes. Clin Chem 1990, 36:1629-1632.
18. Westgard J.O. Six Sigma quality design and control 2006, Westgard QC, Madison (WI). 2nd edition.
19. Westgard J.O., Groth T., Aronsson T., et al. Performance characteristics of rules for internal quality control: probabilities for false rejection and error detection. Clin Chem 1977, 23:1857-1867.
20. Shebl N.A., Franklin B.D., Barber N. Is failure mode and effects analysis reliable?. J Patient Saf 2009, 5:86-94.
21. Shebl N.A., Franklin B.D., Barber N. Failure mode and effects analysis: are they valid?. BMC Health Serv Res 2012, 12:150.
22. Shebl N., Franklin B., Barber N. Failure mode and effects analysis: views of hospital staff in the UK. J Health Serv Res Policy 2012, 17(1):37-43.
23. Shebl N.A., Franklin B.D., Barber N. Failure mode and effects analysis: too little for too much?. BMJ Qual Saf 2012, 21:607-611.
24. Westgard SA. The detectability debate, June 2011. Available at: . Accessed September 25, 2012. http://www.westgard.com/detectability-debate.htm.
25. Westgard SA, Salcedo G. A Six Sigma risk analysis example: defining QC frequency with FMEA. July 2012. Available at: . Accessed September 25, 2012. http://www.westgard.com/endoclab-risk.htm.